Preclinical Data Readout for MDL-001 - Direct-Acting, Broad-Spectrum Antiviral

Get in Touch

Get in Touch

Preclinical Data Readout for MDL-001 - Direct-Acting, Broad-Spectrum Antiviral

Get in Touch

Get in Touch

Preclinical Data Readout for MDL-001 - Direct-Acting, Broad-Spectrum Antiviral

Jan 16, 2020

Jan 16, 2020

Jan 16, 2020

Model Medicines discuss AI Drug Discovery at JPM 2020 Healthcare Week

Exploring the Digital Transformation of Healthcare

Share

LinkedIn

x

Share

Instagram

Twitter

Behance

Details

Date

Jan 16, 2020

Category

Events

Reading

90 Mins

Author

Patrick ONeill

Investor Relations

Related News

Dec 4, 2025

Announcement

Model Medicines Unveils Groundbreaking Preclinical Data: Oral MDL-001 Demonstrates Superiority or Equivalence to Three Standard-of-Care Antivirals: Nirmatrelvir, Remdesivir, and Sofosbuvir, Across Respiratory and Hepatic Viral Diseases

Dec 4, 2025

Announcement

Model Medicines Unveils Groundbreaking Preclinical Data: Oral MDL-001 Demonstrates Superiority or Equivalence to Three Standard-of-Care Antivirals: Nirmatrelvir, Remdesivir, and Sofosbuvir, Across Respiratory and Hepatic Viral Diseases

Dec 4, 2025

Announcement

Model Medicines Unveils Groundbreaking Preclinical Data: Oral MDL-001 Demonstrates Superiority or Equivalence to Three Standard-of-Care Antivirals: Nirmatrelvir, Remdesivir, and Sofosbuvir, Across Respiratory and Hepatic Viral Diseases

Nov 10, 2025

Events

MDL-001 as a Next-Generation HCV Thumb-1 Inhibitor with Clinical-Stage Safety

Nov 10, 2025

Events

MDL-001 as a Next-Generation HCV Thumb-1 Inhibitor with Clinical-Stage Safety

Nov 10, 2025

Events

MDL-001 as a Next-Generation HCV Thumb-1 Inhibitor with Clinical-Stage Safety